The specialty pharmaceutical and generics M&A frenzy that continues to fuel strong sector performance is being driven by a host of factors which could continue to drive M&A activity into 2016, notes Nomura. Shibani Malhotra and Austin Nelson of Nomura in their September 28, 2015 research note on “Equity: Americas Specialty Pharmaceuticals & Generics” believe sector consolidation will continue as the overall pharmaceutical industry witnesses an increasingly challenging macroeconomic environment. M&A remains the driver of value across specialty Pharma and generics sector Malhotra and colleague anticipate further consolidation across the specialty pharma and generics industry, although investors are beginning to…
Specialty Pharma, Generics M&A Frenzy To Continue Into 2016: Nomura
Mani
Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports